Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma

BACKGROUND: This retrospective analysis of data from clinical trials in metastatic urothelial carcinoma (mUC) was conducted to determine baseline patient characteristics associated with long-term survival (LTS) following treatment with immune checkpoint inhibitors. METHODS: Data for this analysis we...

Descripción completa

Detalles Bibliográficos
Autores principales: Alt, Marie, Stecca, Carlos, Lin, Yian, Kazeem, Gbenga, Goluboff, Erik T., Sridhar, Srikala S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540375/
https://www.ncbi.nlm.nih.gov/pubmed/37773115
http://dx.doi.org/10.1186/s12885-023-11380-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540375/
https://www.ncbi.nlm.nih.gov/pubmed/37773115
http://dx.doi.org/10.1186/s12885-023-11380-6

Ejemplares similares